Protein-bound paclitaxel

Protein-bound paclitaxel is an injectable formulation of paclitaxel, a mitotic inhibitor drug used in the treatment of breast cancer. In this formulation, paclitaxel is bonded to albumin as a delivery vehicle. It is sold in the United States under the trade name Abraxane by Abraxis Bioscience

This treatment was approved by the Food and Drug Administration in January 2005 for cases where cancer did not respond to other chemotherapy or has relapsed.

Abraxane is a first in its class of drugs using nanoparticle albumin bound (nab) technology platform. nab Technology

References